3309:TSESekisui House Reit. Inc. Analysis

C‑MER Medical is trading at HK$0.97, comfortably below its 20‑day SMA (0.975) and far under the 200‑day SMA (1.48), indicating a bearish technical backdrop, yet the MACD histogram has turned positive and volume is rising, hinting at a potential short‑term bounce off the support level of HK$0.91. Valuation metrics are compelling: the forward PE of 10.8 and trailing PE of 12.1 are well under the industry average PE of 28.5, while the price‑to‑book of 0.65 and price‑to‑FFO proxy of 4.07 suggest deep discount relative to peers. The DCF‑derived fair value of HK$2.18 implies more than 100% upside from current levels, and the dividend yield of 2.15% with a modest 24% payout adds income appeal. Fundamentally, the company generates HK$1.95 bn in revenue with modest 1.2% growth, maintains a gross margin of 31% and a free cash flow of HK$187 m, and its balance sheet is solid – cash (HK$466 m) exceeds debt (HK$427 m) and debt‑to‑equity sits at just 22%. However, profitability is modest (ROE 5.8%, profit margin 5.2%) and the 30‑day volatility is high at 45%, while historical max drawdown of –57% underscores downside risk. Market sentiment is extremely bullish (Fear & Greed Index 92.2), but the stock’s technical trend remains bearish, creating a mixed short‑term outlook amid strong long‑term fundamentals.